EP2991647A4 - Deuteriertes amlexanox - Google Patents

Deuteriertes amlexanox

Info

Publication number: EP2991647A4
Authority: EP; European Patent Office
Prior art keywords: deutéré; amléxanox; amléxanox deutéré
Prior art date: 2013-05-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP14791582.1A

Other languages

English (en)

French (fr)

Other versions

EP2991647B1 (de

EP2991647A1 (de

Inventor

Alan R Saltiel

Hollis D Showalter

Scott Larsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Michigan System

University of Michigan Ann Arbor

Original Assignee

University of Michigan System

University of Michigan Ann Arbor

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-02

Filing date

2014-05-02

Publication date

2016-10-12

2014-05-02 Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System

2016-03-09 Publication of EP2991647A1 publication Critical patent/EP2991647A1/de

2016-10-12 Publication of EP2991647A4 publication Critical patent/EP2991647A4/de

2019-04-24 Application granted granted Critical

2019-04-24 Publication of EP2991647B1 publication Critical patent/EP2991647B1/de

Status Active legal-status Critical Current

2034-05-02 Anticipated expiration legal-status Critical

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP14791582.1A 2013-05-02 2014-05-02 Deuteriertes amlexanox mit verbesserter metabolischer stabilität Active EP2991647B1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361818753P	2013-05-02	2013-05-02
PCT/US2014/036644 WO2014179734A1 (en)	2013-05-02	2014-05-02	Deuterated amlexanox

Publications (3)

Publication Number	Publication Date
EP2991647A1 EP2991647A1 (de)	2016-03-09
EP2991647A4 true EP2991647A4 (de)	2016-10-12
EP2991647B1 EP2991647B1 (de)	2019-04-24

Family

ID=51841741

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14791582.1A Active EP2991647B1 (de)	2013-05-02	2014-05-02	Deuteriertes amlexanox mit verbesserter metabolischer stabilität

Country Status (4)

Country	Link
US (4)	US9365581B2 (de)
EP (1)	EP2991647B1 (de)
ES (1)	ES2727898T3 (de)
WO (1)	WO2014179734A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2659763T3 (es)	2011-02-14	2018-03-19	The Regents Of The University Of Michigan	Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
WO2014179734A1 (en)	2013-05-02	2014-11-06	The Regents Of The University Of Michigan	Deuterated amlexanox
US10077268B2 (en)	2014-03-13	2018-09-18	Salk Institute For Biological Studies	FXR agonists and methods for making and using
US10301268B2 (en)	2014-03-13	2019-05-28	The Salk Institute For Biological Studies	Analogs of fexaramine and methods of making and using
US10214536B2 (en)	2016-01-29	2019-02-26	The Regents Of The University Of Michigan	Amlexanox analogs
CN112121044B (zh) *	2019-06-25	2023-07-11	青岛海济生物医药有限公司	氨来占诺用于制备抗肝炎病毒药物的用途
CN112704684A (zh) *	2021-01-13	2021-04-27	南京医科大学	敲低或抑制sting活性物质的医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100167989A1 (en) *	2008-10-23	2010-07-01	Auspex Pharmaceuticals, Inc.	Isopropoxyphenylmethyl inhibitors of sglt2
WO2012112558A1 (en) *	2011-02-14	2012-08-23	The Regents Of The University Of Michigan	Compositions and methods for the treatment of obesity and related disorders

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5814668B2 (ja)	1975-11-07	1983-03-22	富士写真フイルム株式会社	シヤシンヨウゲンゾウヤク
US4299963A (en)	1977-03-08	1981-11-10	Takeda Chemical Industries, Ltd.	1-Azaxanthone derivatives
CA1087188A (en)	1977-03-08	1980-10-07	Hirosada Sugihara	1-azaxanthone-3-carboxylic acids
FR2396123A1 (fr)	1977-07-01	1979-01-26	Beaudrey & Cie	Tamis de prise d'eau a dispositif de sauvegarde pour la protection des elements vivants, en particulier poissons, et dispositif de sauvegarde correspondant
US4657760A (en)	1979-03-20	1987-04-14	Ortho Pharmaceutical Corporation	Methods and compositions using monoclonal antibody to human T cells
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4965188A (en)	1986-08-22	1990-10-23	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5206344A (en)	1985-06-26	1993-04-27	Cetus Oncology Corporation	Interleukin-2 muteins and polymer conjugation thereof
US4728509A (en) *	1985-08-19	1988-03-01	Takeda Chemical Industries, Ltd.	Aqueous liquid preparation
DE3785591T2 (de)	1986-01-10	1993-09-02	Amoco Corp	Kompetitiver homogener test.
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5283174A (en)	1987-09-21	1994-02-01	Gen-Probe, Incorporated	Homogenous protection assay
US5130238A (en)	1988-06-24	1992-07-14	Cangene Corporation	Enhanced nucleic acid amplification process
US5225326A (en)	1988-08-31	1993-07-06	Research Development Foundation	One step in situ hybridization assay
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
JP2963496B2 (ja)	1989-06-26	1999-10-18	第一製薬株式会社	ベンゾピラノピリジン誘導体
KR100242252B1 (ko)	1989-07-11	2000-03-02	다니엘 엘. 캐시앙	핵산서열의 증폭방법
CA2020958C (en)	1989-07-11	2005-01-11	Daniel L. Kacian	Nucleic acid sequence amplification methods
US5225212A (en)	1989-10-20	1993-07-06	Liposome Technology, Inc.	Microreservoir liposome composition and method
NZ241311A (en)	1991-01-17	1995-03-28	Gen Hospital Corp	Rna sequence having trans-splicing activity, plant strains
US5455166A (en)	1991-01-31	1995-10-03	Becton, Dickinson And Company	Strand displacement amplification
US5362737A (en)	1991-04-09	1994-11-08	Chemex Pharmaceuticals, Inc.	Methods of treating aphthous ulcers and other mucocutaneous disorders with amlexanox
US5270184A (en)	1991-11-19	1993-12-14	Becton, Dickinson And Company	Nucleic acid target generation
US5545524A (en)	1991-12-04	1996-08-13	The Regents Of The University Of Michigan	Compositions and methods for chromosome region-specific probes
US5470955A (en)	1993-02-02	1995-11-28	Dartmouth College	Antibodies which specifically bind mcl-1 polypeptide
US6924361B1 (en)	1993-11-02	2005-08-02	Phosphoproteomics Llc	Phosphopeptide-specific antibodies that are activity specific; methods of production and antibody uses
US5925517A (en)	1993-11-12	1999-07-20	The Public Health Research Institute Of The City Of New York, Inc.	Detectably labeled dual conformation oligonucleotide probes, assays and kits
US6221335B1 (en) *	1994-03-25	2001-04-24	Isotechnika, Inc.	Method of using deuterated calcium channel blockers
US5648211A (en)	1994-04-18	1997-07-15	Becton, Dickinson And Company	Strand displacement amplification using thermophilic enzymes
JP3189000B2 (ja)	1994-12-01	2001-07-16	東ソー株式会社	特定核酸配列の検出方法
US5710029A (en)	1995-06-07	1998-01-20	Gen-Probe Incorporated	Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product
US5981180A (en)	1995-10-11	1999-11-09	Luminex Corporation	Multiplexed analysis of clinical specimens apparatus and methods
US6074822A (en)	1995-11-03	2000-06-13	Board Of Trustees Operating Michigan State University	Method for testing for risk of diabetes
US6121489A (en)	1996-03-05	2000-09-19	Trega Biosciences, Inc.	Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein
WO1997039008A1 (en)	1996-04-12	1997-10-23	The Public Health Research Institute Of The City Of New York, Inc.	Detection probes, kits and assays
GB9613070D0 (en)	1996-06-21	1996-08-28	Rowett Research Services Limit	Dietary lectins
US6758848B2 (en)	1998-03-03	2004-07-06	Senorx, Inc.	Apparatus and method for accessing a body site
WO2000001850A2 (en)	1998-07-02	2000-01-13	Gen-Probe Incorporated	Molecular torches
US6573043B1 (en)	1998-10-07	2003-06-03	Genentech, Inc.	Tissue analysis and kits therefor
US6316433B1 (en)	1998-12-18	2001-11-13	Kaneka Corporation	Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6309863B1 (en)	1999-01-25	2001-10-30	Brookhaven Science Associates	Methods for generating phosphorylation site-specific immunological reagents
US6673908B1 (en)	1999-02-22	2004-01-06	Nuvelo, Inc.	Tumor necrosis factor receptor 2
ID30176A (id)	1999-03-12	2001-11-08	Boehringer Ingelheim Pharma	Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi
US6303305B1 (en)	1999-03-30	2001-10-16	Roche Diagnostics, Gmbh	Method for quantification of an analyte
DE60014762T2 (de)	1999-05-24	2005-10-13	Tosoh Corp., Shinnanyo	Methode zum Nachweis von Ribonukleinsäuren
US6630312B2 (en)	1999-08-10	2003-10-07	Joslin Diabetes Center, Inc.	Method for identifying compounds for treatment of insulin resistance
GB2356197A (en)	1999-10-12	2001-05-16	Merck & Co Inc	Amide derivatives as beta 3 agonists
PT1104760E (pt) *	1999-12-03	2003-06-30	Pfizer Prod Inc	Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
US20020103219A1 (en)	2000-10-05	2002-08-01	Jeremy Jacob	Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
WO2002064736A2 (en)	2001-01-04	2002-08-22	Myriad Genetics, Inc.	Protein-protein interactions
WO2002071067A1 (en)	2001-03-07	2002-09-12	Bio-Rad Laboratories, Inc.	Assay system for simultaneous detection and measurement of multiple modified cellular proteins
US6900204B2 (en)	2001-09-06	2005-05-31	Activbiotics, Inc.	Antimicrobial agents and uses thereof
FR2830086B1 (fr)	2001-09-27	2004-08-27	Cit Alcatel	Filtre accordable compose d'une fibre optique et procede correspondant
US20030124178A1 (en) *	2001-12-28	2003-07-03	Haley Jeffrey T.	Soft, adherent, soluble oral patch
US20040171809A1 (en)	2002-09-09	2004-09-02	Korsmeyer Stanley J.	BH3 peptides and method of use thereof
WO2004097009A2 (en)	2003-05-01	2004-11-11	Novartis Ag	METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi
AU2004235747B2 (en)	2003-05-01	2009-05-28	Gen-Probe Incorporated	Oligonucleotides comprising a molecular switch
JPWO2005035516A1 (ja)	2003-10-10	2006-12-21	小野薬品工業株式会社	新規縮合複素環化合物およびその用途
AU2004308399A1 (en)	2003-12-23	2005-07-14	Activbiotics, Inc.	Rifamycin analogs and uses thereof
EP1730154B1 (de)	2004-01-13	2012-10-17	Cumbre IP Ventures, L.P.	Gegen arzneimittelresistente mikroben wirksame rifamycinderivate
GB0402809D0 (en)	2004-02-09	2004-03-10	Glaxo Group Ltd	Chemical compounds
US20050282818A1 (en)	2004-06-22	2005-12-22	Rigel Pharmaceuticals, Inc.	Ubiquitin ligase inhibitors
EP1763528B1 (de)	2004-07-05	2008-11-26	Astellas Pharma Inc.	Pyrazolopyridinderivate
EP1789393A2 (de)	2004-07-30	2007-05-30	GPC Biotech AG	Pyridinylamine
EP1975242B1 (de)	2004-08-27	2011-03-02	Gen-Probe Incorporated	Einfach-Primernukleinsäuren-Erweiterungsverfahren
FR2876103B1 (fr)	2004-10-01	2008-02-22	Aventis Pharma Sa	Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20060094682A1 (en)	2004-10-29	2006-05-04	Odyssey Thera, Inc.	Kinase inhibitors for the treatment of diabetes and obesity
US7772255B2 (en)	2005-12-13	2010-08-10	Supratek Pharma, Inc.	Method of treating tumors with azaxanthones
US20070203236A1 (en)	2006-01-11	2007-08-30	Smith Jeffrey W	Novel antagonists of the human fatty acid synthase thioesterase
JP5496877B2 (ja)	2007-04-16	2014-05-21	アッヴィ・インコーポレイテッド	７−置換インドールＭｃｌ−１阻害薬
EP2175845A2 (de)	2007-07-11	2010-04-21	Cardoz AB	Neue kombination zur verwendung bei der behandlung von entzündlichen erkrankungen
WO2009064792A1 (en)	2007-11-16	2009-05-22	Cumbre Pharmaceuticals Inc.	Quinolone carboxylic acid-substituted rifamycin derivatives
CA2719247C (en)	2008-03-25	2017-03-21	The Regents Of The University Of Michigan	Ikki inhibitor therapies and screening methods, and related ikki diagnostics
SI2299999T1 (sl)	2008-06-04	2017-12-29	Baylor Collega Of Medicine	Stat3 inhibitorji
US20100009934A1 (en)	2008-06-09	2010-01-14	Combinatorx, Incorporated	Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US20110086889A1 (en)	2008-06-11	2011-04-14	Hamed Aissaoui	Tetrazole compounds as orexin receptor antagonists
US8673910B2 (en)	2008-06-30	2014-03-18	H. Lee Moffitt Cancer Center And Research Institute	Proteasome inhibitors for selectively inducing apoptosis in cancer cells
NZ593536A (en)	2008-12-19	2013-07-26	Genentech Inc	Quinoline derivatives and methods of use
WO2010102286A2 (en)	2009-03-06	2010-09-10	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Proteasome inhibitors having chymotrypsin-like activity
EP3026052A1 (de)	2009-04-20	2016-06-01	Auspex Pharmaceuticals, Inc.	Vobereitung von deuterierte piperidinhemmer der janus-kinase 3
EP2427183A4 (de)	2009-05-05	2014-01-08	Univ Florida	Therapeutische verbindungen
JP2012528844A (ja) *	2009-06-01	2012-11-15	バイオコピアリミテッド	好中球によって引き起こされる疾患の治療におけるアンレキサノクスの使用
WO2010151799A2 (en)	2009-06-26	2010-12-29	University Of Massachusetts	Compounds for modulating rna binding proteins and uses therefor
CA2786777A1 (en)	2010-01-07	2011-07-14	Akron Molecules Gmbh	Obesity small molecules
EP2600865B1 (de)	2010-08-05	2018-11-14	Université de Lille	Verbindung zur behandlung von nonsense-mutationsvermittelten erkrankungen und pharmazeutische zusammensetzung mit dieser verbindung
WO2012178036A2 (en)	2011-06-22	2012-12-27	Mayo Foundation For Medical Education And Research	Inhibitors of rtt109 as anti-fungal agents
ES2624986T3 (es)	2011-09-13	2017-07-18	Glaxosmithkline Llc	Azaindazoles
US9486422B2 (en)	2011-10-06	2016-11-08	The Regents Of The University Of Michigan	Small molecule inhibitors of Mcl-1 and the uses of thereof
WO2013086415A1 (en)	2011-12-09	2013-06-13	The Regents Of The University Of Michigan	Antimicrobial compounds
WO2014111957A1 (en)	2013-01-21	2014-07-24	Apparao Satyam	Nitric oxide releasing prodrugs of therapeutic agents
WO2014179734A1 (en)	2013-05-02	2014-11-06	The Regents Of The University Of Michigan	Deuterated amlexanox
WO2015119624A1 (en)	2014-02-07	2015-08-13	The Regents Of The University Of Michigan	COMBINATIONS OF IKKε/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS
US20150224089A1 (en)	2014-02-07	2015-08-13	The Regents Of The University Of Michigan	COMBINATIONS OF IKKi/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS
US9394303B2 (en)	2014-04-04	2016-07-19	The Regents Of The University Of Michigan	Small molecule inhibitors of MCL-1 and uses thereof

2014
- 2014-05-02 WO PCT/US2014/036644 patent/WO2014179734A1/en not_active Ceased
- 2014-05-02 EP EP14791582.1A patent/EP2991647B1/de active Active
- 2014-05-02 US US14/888,591 patent/US9365581B2/en not_active Expired - Fee Related
- 2014-05-02 ES ES14791582T patent/ES2727898T3/es active Active
- 2014-05-02 US US14/268,762 patent/US8946424B2/en active Active
2016
- 2016-05-12 US US15/153,405 patent/US9944652B2/en active Active
2018
- 2018-04-16 US US15/953,907 patent/US10590142B2/en not_active Expired - Fee Related

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100167989A1 (en) *	2008-10-23	2010-07-01	Auspex Pharmaceuticals, Inc.	Isopropoxyphenylmethyl inhibitors of sglt2
WO2012112558A1 (en) *	2011-02-14	2012-08-23	The Regents Of The University Of Michigan	Compositions and methods for the treatment of obesity and related disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014179734A1 *

Also Published As

Publication number	Publication date
WO2014179734A1 (en)	2014-11-06
EP2991647B1 (de)	2019-04-24
US8946424B2 (en)	2015-02-03
US10590142B2 (en)	2020-03-17
US20160060271A1 (en)	2016-03-03
US20160251366A1 (en)	2016-09-01
US9944652B2 (en)	2018-04-17
US20180230161A1 (en)	2018-08-16
US20140329848A1 (en)	2014-11-06
ES2727898T3 (es)	2019-10-21
EP2991647A1 (de)	2016-03-09
US9365581B2 (en)	2016-06-14

Publication	Publication Date	Title
DK3342773T3 (da)	2021-02-15	Syk-hæmmere
DK3613453T3 (da)	2021-10-11	Fordamper
DK3077047T3 (da)	2019-07-15	Aramcholsalte
DK3052081T3 (da)	2021-01-18	Pastil
DK3060460T3 (da)	2021-04-19	Saddel
DK3027598T3 (da)	2017-05-22	Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da)	2021-03-22	Bindestrimler
DK2946640T3 (da)	2017-11-20	Langmuir-probe
EP2943489A4 (de)	2016-06-08	Deuteriertes momelotinib
DE102013106534B8 (de)	2015-06-18	Chromatographiepipettenspitze
EP2991647A4 (de)	2016-10-12	Deuteriertes amlexanox
EP2970310A4 (de)	2016-09-07	5-brom-indirubine
EP2853297A4 (de)	2016-02-24	Kendama
DK3071227T3 (da)	2021-01-18	Fiskevaccine
DE112014001252A5 (de)	2016-01-21	Aufbissschiene
DK3086679T3 (da)	2020-10-26	Sportssko
DK2981168T3 (da)	2020-04-06	Laminitiskile
FI10343U1 (fi)	2013-12-31	Mittateippi
FI10138U1 (fi)	2013-06-28	Kelkkateltta
ES1078715Y (es)	2013-12-02	Mosquitera
DE112014005422A5 (de)	2016-09-01	Friktionsfalschdrallaggregat
ES1100380Y (es)	2014-05-14	Trompo
ES1093505Y (es)	2014-02-11	Aerociclo
ES1096481Y (es)	2014-03-14	Ecofregona
ES1093455Y (es)	2014-02-11	Columbario

Legal Events

Date	Code	Title	Description
2016-02-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-03-09	17P	Request for examination filed	Effective date: 20151110
2016-03-09	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-03-09	AX	Request for extension of the european patent	Extension state: BA ME
2016-08-10	DAX	Request for extension of the european patent (deleted)
2016-10-12	A4	Supplementary search report drawn up and despatched	Effective date: 20160908
2016-10-12	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/436 20060101ALI20160902BHEP Ipc: C07D 491/052 20060101AFI20160902BHEP Ipc: A61P 31/04 20060101ALI20160902BHEP Ipc: A61P 31/10 20060101ALI20160902BHEP
2017-07-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602014045426 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031436000 Ipc: C07D0491052000
2017-08-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2017-08-30	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 31/10 20060101ALI20170724BHEP Ipc: A61K 31/436 20060101ALI20170724BHEP Ipc: A61P 31/04 20060101ALI20170724BHEP Ipc: C07D 491/052 20060101AFI20170724BHEP
2017-09-13	17Q	First examination report despatched	Effective date: 20170811
2018-07-17	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-07-17	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-08-15	INTG	Intention to grant announced	Effective date: 20180718
2018-11-19	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2018-11-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-12-26	INTC	Intention to grant announced (deleted)
2019-01-08	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2019-01-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2019-01-30	INTG	Intention to grant announced	Effective date: 20190109
2019-03-15	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2019-03-22	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2019-03-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2019-04-24	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-04-24	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2019-04-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2019-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 1124012 Country of ref document: AT Kind code of ref document: T Effective date: 20190515 Ref country code: IE Ref legal event code: FG4D
2019-05-16	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602014045426 Country of ref document: DE
2019-08-28	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20190424
2019-09-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2019-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424
2019-10-21	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2727898 Country of ref document: ES Kind code of ref document: T3 Effective date: 20191021
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190824 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190724 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424
2019-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190724 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190725
2019-12-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1124012 Country of ref document: AT Kind code of ref document: T Effective date: 20190424
2019-12-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2019-12-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190824
2020-01-27	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602014045426 Country of ref document: DE
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424
2020-02-05	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20190531
2020-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190502 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424
2020-02-28	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2020-02-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424
2020-04-01	26N	No opposition filed	Effective date: 20200127
2020-05-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190502
2020-05-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424
2021-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424
2021-07-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140502
2022-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190424
2023-06-21	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230511
2024-07-08	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20240507 Year of fee payment: 11
2024-07-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20240517 Year of fee payment: 11
2024-07-22	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20240614 Year of fee payment: 11
2024-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20240523 Year of fee payment: 11
2024-09-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IT Payment date: 20240531 Year of fee payment: 11